Interpace Biosciences, Inc. (IDXG) income statement
IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 63.7%
- Operating margin
- 11.5%
- Net margin
- 67.6%
- Return on equity, FY2025
- 244.0%
Financial strength
- Current ratio
- 2.22
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 54.3%
Valuation
- P/E ratio
- 5.6
- Price to sales
- 3.83
- Price to book
- 5.96
- Dividend yield
- –
See a number that looks wrong?